Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015 (2015), Article ID 723093, 9 pages
http://dx.doi.org/10.1155/2015/723093
Review Article

Potential Benefits of Berberine in the Management of Perimenopausal Syndrome

1Department of Medical Sciences, University of Ferrara, Ferrara, Italy
2Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy
3Department of Medicine and Surgery Sciences, University of Bologna, Bologna, Italy

Received 27 November 2014; Accepted 28 January 2015

Academic Editor: Angel Catalá

Copyright © 2015 Cristiana Caliceti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Conroy, K. Pyörälä, A. P. Fitzgerald et al., “Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project,” European Heart Journal, vol. 24, no. 11, pp. 987–1003, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. A. F. G. Cicero, E. Tartagni, A. Ferroni, V. de Sando, E. Grandi, and C. Borghi, “Combined nutraceutical approach to postmenopausal syndrome and vascular remodeling biomarkers,” The Journal of Alternative and Complementary Medicine, vol. 19, no. 6, pp. 582–587, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. L. Gudmundsdottir, W. D. Flanders, and L. B. Augestad, “Physical activity and cardiovascular risk factors at menopause: the Nord-Trondelag health study,” Climacteric, vol. 16, no. 4, pp. 438–446, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. B. Doshi and A. Agarwal, “The role of oxidative stress in menopause,” Journal of Mid-Life Health, vol. 4, no. 3, pp. 140–146, 2013. View at Publisher · View at Google Scholar
  5. S. Spinozzi, C. Colliva, C. Camborata et al., “Berberine and its metabolites: relationship between physicochemical properties and plasma levels after administration to human subjects,” Journal of Natural Products, vol. 77, no. 4, pp. 766–772, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Maynar, G. Mahedero, I. Maynar, J. I. Maynar, I. R. Tuya, and M. J. Caballero, “Menopause-induced changes in lipid fractions and total fatty acids in plasma,” Endocrine Research, vol. 27, no. 3, pp. 357–365, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. L. M. Yung, W. T. Wong, X. Y. Tian et al., “Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats,” PLoS ONE, vol. 6, no. 3, Article ID e17437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Halliwell, “Free radicals and antioxidants: updating a personal view,” Nutrition Reviews, vol. 70, no. 5, pp. 257–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. V. A. Barbosa, T. F. Luciano, S. O. Marques et al., “Acute exercise induce endothelial nitric oxide synthase phosphorylation via Akt and AMP-activated protein kinase in aorta of rats: Role of reactive oxygen species,” International Journal of Cardiology, vol. 167, no. 6, pp. 2983–2988, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Taddei, A. Virdis, L. Ghiadoni et al., “Menopause is associated with endothelial dysfunction in women,” Hypertension, vol. 28, no. 4, pp. 576–582, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. N. G. Majmudar, S. C. Robson, and G. A. Ford, “Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 4, pp. 1577–1583, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Wassmann, A. T. Bäumer, K. Strehlow et al., “Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats,” Circulation, vol. 103, no. 3, pp. 435–441, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. S. S. Signorelli, S. Neri, S. Sciacchitano et al., “Behaviour of some indicators of oxidative stress in postmenopausal and fertile women,” Maturitas, vol. 53, no. 1, pp. 77–82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. R. McLean, “Proinflammatory cytokines and osteoporosis,” Current Osteoporosis Reports, vol. 7, no. 4, pp. 134–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. R. S. Frey, M. Ushio-Fukai, and A. B. Malik, “NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology,” Antioxidants and Redox Signaling, vol. 11, no. 4, pp. 791–810, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Furukawa, T. Fujita, M. Shimabukuro et al., “Increased oxidative stress in obesity and its impact on metabolic syndrome,” The Journal of Clinical Investigation, vol. 114, no. 12, pp. 1752–1761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Bonnefont-Rousselot, “Glucose and reactive oxygen species,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 5, no. 5, pp. 561–568, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, “Advanced glycation end products: sparking the development of diabetic vascular injury,” Circulation, vol. 114, no. 6, pp. 597–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Cheng, Y. Wang, J. Li et al., “Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans,” International Journal of Cardiology, vol. 167, no. 3, pp. 936–942, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. L. K. Sarna, N. Wu, S.-Y. Hwang, Y. L. Siow, and O. Karmin, “Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages,” Canadian Journal of Physiology and Pharmacology, vol. 88, no. 3, pp. 369–378, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-S. Hsieh, W.-H. Kuo, T.-W. Lin et al., “Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells,” Journal of Agricultural and Food Chemistry, vol. 55, no. 25, pp. 10437–10445, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Cheng, Y. Wang, J. Li et al., “Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans,” International Journal of Cardiology, vol. 167, no. 3, pp. 936–942, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. J.-E. Kim, Y.-W. Kim, K. L. In, J.-Y. Kim, J. K. Young, and S.-Y. Park, “AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide- 1-β-d-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression,” Journal of Pharmacological Sciences, vol. 106, no. 3, pp. 394–403, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Wang, M. Zhang, B. Liang et al., “AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H Oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes,” Circulation Research, vol. 106, no. 6, pp. 1117–1128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Ceolotto, A. Gallo, I. Papparella et al., “Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2627–2633, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. K.-H. Lee, H.-L. Lo, W.-C. Tang, H. H. Hsiao, and P.-M. Yang, “A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine,” Scientific Reports, vol. 4, article 6394, 2014. View at Publisher · View at Google Scholar
  27. N. Turner, J.-Y. Li, A. Gosby et al., “Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate amp-activated protein kinase and improve insulin action,” Diabetes, vol. 57, no. 5, pp. 1414–1418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Li, Y.-N. Geng, J.-D. Jiang, and W.-J. Kong, “Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 289264, 12 pages, 2014. View at Publisher · View at Google Scholar
  29. V. A. Morrow, F. Foufelle, J. M. C. Connell, J. R. Petrie, G. W. Gould, and I. P. Salt, “Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells,” Journal of Biological Chemistry, vol. 278, no. 34, pp. 31629–31639, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. K. M. Gavin, D. R. Seals, A. E. Silver, and K. L. Moreau, “Vascular endothelial estrogen receptor α is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3513–3520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Loyer, T. Damy, Z. Chvojkova et al., “17beta-estradiol regulates constitutive nitric oxide synthase expression differentially in the myocardium in response to pressure overload,” Endocrinology, vol. 148, no. 10, pp. 4579–4584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Zhang, C.-M. Wang, J. Li et al., “Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4,” Mediators of Inflammation, vol. 2013, Article ID 260464, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Wang, Y. Huang, K. S. L. Lam et al., “Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase,” Cardiovascular Research, vol. 82, no. 3, pp. 484–492, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Kukidome, T. Nishikawa, K. Sonoda et al., “Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells,” Diabetes, vol. 55, no. 1, pp. 120–127, 2006. View at Google Scholar · View at Scopus
  35. Z. Xie, J. Zhang, J. Wu, B. Viollet, and M.-H. Zou, “Upregulation of mitochondrial uncoupling protein-2 by the AMP-Activated protein kinase in endothelial cells attenuates oxidative stress in diabetes,” Diabetes, vol. 57, no. 12, pp. 3222–3230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Chatuphonprasert, T. Lao-Ong, and K. Jarukamjorn, “Improvement of superoxide dismutase and catalase in streptozotocin–nicotinamide-induced type 2-diabetes in mice by berberine and glibenclamide,” Pharmaceutical Biology, vol. 52, no. 4, pp. 419–427, 2014. View at Publisher · View at Google Scholar
  37. T. Lao-Ong, W. Chatuphonprasert, N. Nemoto, and K. Jarukamjorn, “Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine,” Pharmaceutical Biology, vol. 50, no. 8, pp. 1007–1012, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Ceballos-Picot, V. Witko-Sarsat, M. Merad-Boudia et al., “Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure,” Free Radical Biology and Medicine, vol. 21, no. 6, pp. 845–853, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. A. E. Abd El-Wahab, D. A. Ghareeb, E. E. M. Sarhan, M. M. Abu-Serie, and M. A. El Demellawy, “In vitro biological assessment of berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects,” BMC Complementary and Alternative Medicine, vol. 13, article 218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. Y.-Y. Hsu, C.-S. Chen, S.-N. Wu, Y.-J. Jong, and Y.-C. Lo, “Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase/Akt-dependent mechanism in NSC34 motor neuron-like cells,” European Journal of Pharmaceutical Sciences, vol. 46, no. 5, pp. 415–425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Barrett-Connor and T. L. Bush, “Estrogen and coronary heart disease in women,” Journal of the American Medical Association, vol. 265, no. 14, pp. 1861–1867, 1991. View at Publisher · View at Google Scholar · View at Scopus
  42. A. P. Miller, W. Feng, D. Xing et al., “Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries,” Circulation, vol. 110, no. 12, pp. 1664–1669, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. L. C. N. Erberich, V. M. Alcântara, G. Picheth, and M. Scartezini, “Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels,” Clinical Chemistry and Laboratory Medicine, vol. 40, no. 5, pp. 446–451, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Grady, W. Applegate, T. Bush, C. Furberg, B. Riggs, and S. B. Hulley, “Heart and estrogen/progestin replacement study (HERS): design, methods, and baseline characteristics,” Controlled Clinical Trials, vol. 19, no. 4, pp. 314–335, 1998. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Lagro-Janssen, W. W. Rosser, and C. Van Weel, “Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces,” The Lancet, vol. 362, no. 9382, pp. 414–415, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Lubrano and S. Balzan, “LOX-1 and ROS, inseparable factors in the process of endothelial damage,” Free Radical Research, vol. 48, no. 8, pp. 841–848, 2014. View at Publisher · View at Google Scholar
  47. W.-J. Kong, J. Liu, and J.-D. Jiang, “Human low-density lipoprotein receptor gene and its regulation,” Journal of Molecular Medicine, vol. 84, no. 1, pp. 29–36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Cominacini, M. Anselmi, U. Garbin et al., “Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-kappa B activation in patients with unstable angina,” Journal of the American College of Cardiology, vol. 46, no. 5, pp. 799–806, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Pirillo and A. L. Catapano, “Soluble lectin-like oxidized low density lipoprotein receptor-1 as a biochemical marker for atherosclerosis-related diseases,” Disease Markers, vol. 35, no. 5, pp. 413–418, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. J. L. Witztum, “The oxidation hypothesis of atherosclerosis,” The Lancet, vol. 344, no. 8925, pp. 793–795, 1994. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Ehara, M. Ueda, T. Naruko et al., “Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes,” Circulation, vol. 103, no. 15, pp. 1955–1960, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Arjuman, H. Pandey, and N. C. Chandra, “Effect of a combination oral contraceptive (desogestrel+ethinyl estradiol) on the expression of low-density lipoprotein receptor and its transcription factor (SREBP2) in placental trophoblast cells,” Contraception, vol. 84, no. 2, pp. 160–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Ramakrishnan, A. Rana, C. Das, and N. C. Chandra, “Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue,” Contraception, vol. 76, no. 4, pp. 297–305, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Pandey, A. Arjuman, K. K. Roy, and N. C. Chandra, “Reciprocal coordination of a combination oral contraceptive containing desogestrel+ethinyl estradiol on the expression of LOX-1 and LDLR in placental trophoblast cells,” Contraception, vol. 84, no. 6, pp. e43–e49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Yang, D. Q. Song, Y. H. Li et al., “Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 16, pp. 4675–4677, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Abidi, Y. Zhou, J.-D. Jiang, and J. Liu, “Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2170–2176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Kong, J. Wei, P. Abidi et al., “Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins,” Nature Medicine, vol. 10, no. 12, pp. 1344–1351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. Y.-J. Jia, R.-X. Xu, J. Sun, Y. Tang, and J.-J. Li, “Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats,” Journal of Translational Medicine, vol. 12, no. 1, article 103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. W.-J. Kong, J. Wei, Z.-Y. Zuo et al., “Combination of simvastatin with berberine improves the lipid-lowering efficacy,” Metabolism, vol. 57, no. 8, pp. 1029–1037, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Guan, B. Wang, W. Li, J. Guan, and X. Fang, “Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL,” The American Journal of Chinese Medicine, vol. 38, no. 6, pp. 1161–1169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. Z. Huang, F. Dong, S. Li et al., “Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages,” European Journal of Pharmacology, vol. 690, no. 1–3, pp. 164–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Chi, L. Peng, N. Pan, X. Hu, and Y. Zhang, “The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1,” International Journal of Molecular Medicine, vol. 34, no. 4, pp. 1087–1093, 2014. View at Publisher · View at Google Scholar
  63. L. Chi, L. Peng, X. Hu, N. Pan, and Y. Zhang, “Berberine combined with atorvastatin downregulates LOX1 expression through the ET1 receptor in monocyte/macrophages,” International Journal of Molecular Medicine, vol. 34, no. 1, pp. 283–290, 2014. View at Publisher · View at Google Scholar
  64. M. Xiao, L. N. Men, M. G. Xu, G. B. Wang, H. T. Lv, and C. Liu, “Berberine protects endothelial progenitor cell from damage of TNF-α via the PI3K/AKT/eNOS signaling pathway,” European Journal of Pharmacology, vol. 743, pp. 11–16, 2014. View at Publisher · View at Google Scholar
  65. Y.-H. Wu, S.-Y. Chuang, W.-C. Hong, Y.-J. Lai, G.-J. Chang, and J.-H. S. Pang, “Berberine reduces leukocyte adhesion to lps-stimulated endothelial cells and VCAM-1 expression both in vivo and in vitro,” International Journal of Immunopathology and Pharmacology, vol. 25, no. 3, pp. 741–750, 2012. View at Google Scholar · View at Scopus
  66. A. F. Cicero, E. Tartagni, and S. Ertek, “Nutraceuticals for metabolic syndrome management: from laboratory to benchside,” Current Vascular Pharmacology, vol. 12, no. 4, pp. 565–571, 2014. View at Publisher · View at Google Scholar
  67. A. Cianci, A. F. G. Cicero, N. Colacurci, M. G. Matarazzo, and V. de Leo, “Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women,” Gynecological Endocrinology, vol. 28, no. 9, pp. 699–702, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Meng, L.-S. Wang, Z.-Q. Huang et al., “Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention,” Clinical and Experimental Pharmacology and Physiology, vol. 39, no. 5, pp. 406–411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. M. I. Harris, K. M. Flegal, C. C. Cowie et al., “Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988–1994,” Diabetes Care, vol. 21, no. 4, pp. 518–524, 1998. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. E. L. Ding, Y. Song, V. S. Malik, and S. Liu, “Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 295, no. 11, pp. 1288–1299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. S. I. Taylor, D. Accili, and Y. Imai, “Insulin resistance or insulin deficiency: which is the primary cause of NIDDM?” Diabetes, vol. 43, no. 6, pp. 735–740, 1994. View at Publisher · View at Google Scholar · View at Scopus
  73. B. Zhang, G. Salituro, D. Szalkowski et al., “Discovery of a small molecule insulin mimetic with antidiabetic activity in mice,” Science, vol. 284, no. 5416, pp. 974–977, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. D. Foti, E. Chiefari, M. Fedele et al., “Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice,” Nature Medicine, vol. 11, no. 7, pp. 765–773, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Xu, J. Lin, S. Wang, J. Xiong, and Q. Zhu, “Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus,” Kaohsiung Journal of Medical Sciences, vol. 30, no. 7, pp. 350–361, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Morán, P. Garrido, E. Cabello, A. Alonso, and C. González, “Effects of estradiol and genistein on the insulin signaling pathway in the cerebral cortex of aged female rats,” Experimental Gerontology C, vol. 58, pp. 104–112, 2014. View at Publisher · View at Google Scholar
  77. J. Yin, Z. Gao, D. Liu, Z. Liu, and J. Ye, “Berberine improves glucose metabolism through induction of glycolysis,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 294, no. 1, pp. E148–E156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. W. Chang, M. Zhang, J. Li et al., “Berberine improves insulin resistance in cardiomyocytes via activation of 5′-adenosine monophosphate-activated protein kinase,” Metabolism: Clinical and Experimental, vol. 62, no. 8, pp. 1159–1167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. L.-Z. Liu, S. C. K. Cheung, L.-L. Lan et al., “Berberine modulates insulin signaling transduction in insulin-resistant cells,” Molecular and Cellular Endocrinology, vol. 317, no. 1-2, pp. 148–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. W.-J. Kong, H. Zhang, D.-Q. Song et al., “Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression,” Metabolism, vol. 58, no. 1, pp. 109–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Zhang, J. Wei, R. Xue et al., “Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression,” Metabolism: Clinical and Experimental, vol. 59, no. 2, pp. 285–292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Cicero and E. Tartagni, “Antidiabetic properties of berberine: from cellular pharmacology to clinical effects,” Hospital Practice, vol. 40, no. 2, pp. 56–63, 2012. View at Publisher · View at Google Scholar
  83. E. Toffol, O. Heikinheimo, and T. Partonen, “Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review,” Menopause, 2014. View at Publisher · View at Google Scholar
  84. D. L. Goldenberg, “Pain/depression dyad: a key to a better understanding and treatment of functional somatic syndromes,” The American Journal of Medicine, vol. 123, no. 8, pp. 675–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. F.-M. Werner and R. Coveñas, “Classical neurotransmitters and neuropeptides involved in major depression: a review,” International Journal of Neuroscience, vol. 120, no. 7, pp. 455–470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Maes, P. Galecki, Y. S. Chang, and M. Berk, “A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 3, pp. 676–692, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Dowlati, N. Herrmann, W. Swardfager et al., “A meta-analysis of cytokines in major depression,” Biological Psychiatry, vol. 67, no. 5, pp. 446–457, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. B. P. Guiard, M. El Mansari, and P. Blier, “Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors,” Current Drug Targets, vol. 10, no. 11, pp. 1069–1084, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Herken, A. Gurel, S. Selek et al., “Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment,” Archives of Medical Research, vol. 38, no. 2, pp. 247–252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Sarandol, E. Sarandol, S. S. Eker, S. Erdinc, E. Vatansever, and S. Kirli, “Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative—antioxidative systems,” Human Psychopharmacology, vol. 22, no. 2, pp. 67–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. C. K. Sen and L. Packer, “Antioxidant and redox regulation of gene transcription,” FASEB Journal, vol. 10, no. 7, pp. 709–720, 1996. View at Google Scholar · View at Scopus
  92. C. L. Raison, L. Capuron, and A. H. Miller, “Cytokines sing the blues: inflammation and the pathogenesis of depression,” Trends in Immunology, vol. 27, no. 1, pp. 24–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Studd, “Personal view: hormones and depression in women,” Climacteric, vol. 18, no. 1, pp. 3–5, 2014. View at Publisher · View at Google Scholar
  94. P. V. Rekkas, A. A. Wilson, V. W. H. Lee et al., “Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography,” JAMA Psychiatry, vol. 71, no. 8, pp. 873–879, 2014. View at Publisher · View at Google Scholar
  95. S. K. Kulkarni and A. Dhir, “On the mechanism of antidepressant-like action of berberine chloride,” European Journal of Pharmacology, vol. 589, no. 1–3, pp. 163–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. W.-H. Peng, K.-L. Lo, Y.-H. Lee, T.-H. Hung, and Y.-C. Lin, “Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice,” Life Sciences, vol. 81, no. 11, pp. 933–938, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. C. H. K. Cheng, “Monoamine oxidase inhibitors from rhizoma of Coptis chinensis,” Planta Medica, vol. 67, no. 1, pp. 74–76, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Oe, M. Tsukamoto, and Y. Nagakura, “Reserpine causes biphasic nociceptive sensitivity alteration in conjunction with brain biogenic amine tones in rats,” Neuroscience, vol. 169, no. 4, pp. 1860–1871, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. V. Arora and K. Chopra, “Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model,” Journal of Affective Disorders, vol. 151, no. 3, pp. 1041–1052, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. S. K. Kulkarni and A. Dhir, “σ-1 receptors in major depression and anxiety,” Expert Review of Neurotherapeutics, vol. 9, no. 7, pp. 1021–1034, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. A. F. G. Cicero, A. Ferroni, and S. Ertek, “Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects,” Expert Opinion on Drug Safety, vol. 11, no. 5, pp. 753–766, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Sabir and N. K. Bhide, “Study of some pharmacological actions of berberine,” Indian Journal of Physiology and Pharmacology, vol. 15, no. 3, pp. 111–132, 1971. View at Google Scholar · View at Scopus
  103. E. Küpeli, M. Koşar, E. Yeşilada, and K. H. C. Başer, “A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish Berberis species,” Life Sciences, vol. 72, no. 6, pp. 645–657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. H.-W. Xin, X.-C. Wu, Q. Li, A.-R. Yu, M.-Y. Zhong, and Y.-Y. Liu, “The effects of berberine on the pharmacokinetics of ciclosporin A in healthy volunteers,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 28, no. 1, pp. 25–29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. E. Chan, “Displacement of bilirubin from albumin by berberine,” Biology of the Neonate, vol. 63, no. 4, pp. 201–208, 1993. View at Publisher · View at Google Scholar · View at Scopus
  106. F. Affuso, V. Mercurio, V. Fazio, and S. Fazio, “Cardiovascular and metabolic effects of Berberine,” World Journal of Cardiology, vol. 2, no. 4, pp. 71–77, 2010. View at Publisher · View at Google Scholar
  107. H. L. Lin, T. Y. Liu, C. W. Wu, and C. W. Chi, “Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel,” British Journal of Cancer, vol. 81, no. 3, pp. 416–422, 1999. View at Publisher · View at Google Scholar · View at Scopus
  108. R. Vrzal, A. Zdařilová, J. Ulrichová, L. Bláha, J. P. Giesy, and Z. Dvořák, “Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: biphasic effect on CYP1A1,” Biochemical Pharmacology, vol. 70, no. 6, pp. 925–936, 2005. View at Publisher · View at Google Scholar · View at Scopus